FULGENT GENETIC (NASDAQ:FLGT) issued its quarterly earnings data on Monday, August 7th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.02, Bloomberg Earnings reports. FULGENT GENETIC had a negative net margin of 0.42% and a negative return on equity of 0.02%. The company had revenue of $4.64 million during the quarter, compared to the consensus estimate of $5.03 million.

FULGENT GENETIC (NASDAQ:FLGT) traded down 2.65% during trading on Friday, reaching $5.88. 7,077 shares of the company’s stock traded hands. FULGENT GENETIC has a 52-week low of $4.49 and a 52-week high of $13.90. The company’s 50 day moving average is $6.24 and its 200-day moving average is $8.63. The stock’s market cap is $104.31 million.

TRADEMARK VIOLATION NOTICE: “FULGENT GENETIC (FLGT) Issues Quarterly Earnings Results” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/19/fulgent-genetic-flgt-issues-quarterly-earnings-results-updated.html.

FLGT has been the subject of several recent research reports. Zacks Investment Research upgraded shares of FULGENT GENETIC from a “sell” rating to a “hold” rating in a report on Thursday, April 27th. Credit Suisse Group cut their target price on shares of FULGENT GENETIC from $11.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday, August 8th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $7.00 target price (down previously from $10.00) on shares of FULGENT GENETIC in a research note on Wednesday, August 9th.

In other FULGENT GENETIC news, CFO Paul Kim sold 6,134 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $5.71, for a total transaction of $35,025.14. Following the transaction, the chief financial officer now owns 388,602 shares in the company, valued at $2,218,917.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ming Hsieh purchased 30,000 shares of the stock in a transaction on Tuesday, June 13th. The shares were acquired at an average price of $4.98 per share, for a total transaction of $149,400.00. Following the transaction, the insider now directly owns 6,459,944 shares of the company’s stock, valued at approximately $32,170,521.12. The disclosure for this purchase can be found here.

FULGENT GENETIC Company Profile

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Receive News & Stock Ratings for FULGENT GENETIC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FULGENT GENETIC and related stocks with our FREE daily email newsletter.